

1 **COVID-19: impact of original, Gamma, Delta, and**
2 **Omicron variants of SARS-CoV-2 in vaccinated and**
3 **unvaccinated pregnant and postpartum women**

4
5 Fabiano Elisei Serra^{1,2,3*}, Elias Ribeiro Rosa Junior⁴, Patricia de Rossi^{2,5}, Rossana
6 Pulcineli Vieira Francisco¹, and Agatha Sacramento Rodrigues^{1,4}

7
8 ¹ Department of Obstetrics and Gynecology, University of Sao Paulo (USP), Sao Paulo,
9 Brazil

10 ² Course of Medicine, University of Santo Amaro (UNISA), Sao Paulo, Sao Paulo, Brazil

11 ³ Department of Obstetrics, Interlagos Hospital and Maternity, Sao Paulo, Sao Paulo,
12 Brazil

13 ⁴ Department of Statistics, Federal University of Espirito Santo, Vitoria, Espirito Santo,
14 Brazil

15 ⁵ Department of Perinatology and Gynecology, Mandaqui Hospital, Sao Paulo, Sao
16 Paulo, Brazil

17
18 *Corresponding author

19 E-mail: fabianoserra@usp.br (ASR)

20 Postal address: Universidade de São Paulo, Faculdade de Medicina da Universidade
21 de São Paulo. Avenida Dr. Enéas de Carvalho Aguiar, 255 - ICHC- 10º andar- sala
22 10084

23 Cerqueira César - CEP 05403-000 - São Paulo, SP - Brasil

24
25
26 Word count: 2,610

29 **ABSTRACT**

30 **Introduction** This study compares the clinical characteristics and disease progression
31 of vaccinated and unvaccinated pregnant and postpartum women positive for the
32 original, Gamma, Delta, and Omicron variants of severe acute respiratory syndrome
33 coronavirus 2 (SARS-CoV-2) using Brazilian epidemiological data.

34 **Methods** Data of pregnant or postpartum patients with coronavirus disease 2019
35 (COVID-19) SARS-CoV-2 confirmed using polymerase chain reaction from February
36 2020 to July 2022 were extracted from a Brazilian national database. The patients were
37 divided based on vaccination status and viral variant (original, Gamma, Delta, and
38 Omicron). The patients' demographic data, clinical characteristics, comorbidities, signs,
39 symptoms, and outcomes were retrospectively compared.

40 **Results** Data from 10,003 pregnant and 2,361 postpartum women were extracted from
41 the database. Among unvaccinated patients, postpartum women were more likely to be
42 admitted to the intensive care unit (ICU). These patients were more likely to require
43 invasive ventilation when infected with the original, Gamma, and Omicron variants and
44 were more likely to die when infected with the original and Gamma variants. Patients
45 who were vaccinated had reduced adverse outcomes including ICU admission,
46 requirement for invasive ventilation, and death.

47 **Conclusion** Postpartum women were more likely to develop severe COVID-19 that
48 required ICU admission or invasive ventilatory support or led to death, among all
49 variants, especially when the patients were unvaccinated. Therefore, the risk of severe
50 COVID-19 should not be underestimated after delivery. Vaccinated patients had a lower
51 risk of severe outcomes. Vaccination should be a top priority in pregnant and
52 postpartum patients.

53

54 **KEYWORDS**

55 COVID-19, SARS-CoV-2, vaccine, pregnancy, postpartum

56

57

58

59

60 **WHAT IS ALREADY KNOWN ON THIS TOPIC**

61 The obstetric population has a higher risk of adverse outcomes due to coronavirus
62 disease 2019 (COVID-19). Few studies have compared the outcomes of pregnant and
63 postpartum patients or vaccinated and unvaccinated patients; however, no studies have
64 separately investigated the effects of each viral variant.

65 **WHAT THIS STUDY ADDS**

66 Postpartum women are more likely to have adverse outcomes, including the
67 requirements for intensive care and invasive ventilation and death, compared with
68 pregnant women. Vaccinated women had fewer adverse outcomes. The viral variants
69 did not significantly affect the outcomes of these patients.

70 **HOW THIS STUDY MIGHT AFFECT RESEARCH,**
71 **PRACTICE, OR POLICY**

72 The risks of COVID-19 infection should not be underestimated in postpartum women.
73 Postpartum women infected with COVID-19, especially those who are not vaccinated,
74 should be monitored carefully. Vaccination should be a top priority in pregnant and
75 postpartum women.

76 INTRODUCTION

77 Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome
78 coronavirus 2 (SARS-CoV-2), which was first reported in Wuhan, China in December
79 2019. COVID-19 was declared a pandemic in March 2020.[1] As of 26 August 2022,
80 over 596 million cases and 6.4 million deaths have been reported worldwide.[2]

81 COVID-19 affects several systems, with a clinical spectrum ranging from asymptomatic
82 to severe and critical disease. Morbidity and mortality among pregnant women and
83 perinatal outcomes are significant concerns. Initial studies did not report a higher
84 mortality rate or more severe disease in obstetric patients with COVID-19; however,
85 later studies reported that obstetric patients had a higher risk of intensive care
86 admission, requiring invasive ventilation, and death, compared with nonpregnant
87 women.[3-11]

88 During the course of the pandemic, SARS-CoV-2 developed mutations, resulting in new
89 variants. Variants of concern (VOCs) have higher transmissibility, increased virulence,
90 and altered COVID-19 epidemiology and presentation. The effectiveness of public
91 health, social measures, and available therapeutics decreases for VOCs.[12] As of July
92 30, 2022, three VOCs have been detected in Brazil: the Gamma, Delta, and Omicron
93 variants.[13]

94 A high number of maternal deaths due to COVID-19 has been reported in Brazil,
95 including 124 deaths as of 18 June 2020,[14] and 295 maternal deaths have been
96 confirmed using reverse transcriptase polymerase chain reaction (RT-PCR) as of 2
97 January 2021. Puerperal women have a higher risk of serious outcomes (such as
98 intensive care unit (ICU) admission, requirement for invasive and non-invasive
99 ventilatory support, and death) than pregnant women do.[15] The Brazilian Obstetric
100 Observatory for COVID-19 was created on 7 April 2021, and it provides updated data
101 released by the Ministry of Health of Brazil. In total, 1,031 maternal deaths due to
102 COVID-19 (including 680 pregnant women and 351 postpartum women) were reported
103 in Brazil as of 5 May 2021.[16] Even after vaccination campaigns began for pregnant
104 and postpartum women in Brazil on 1 May 2021, pregnant and postpartum women
105 continued to have higher risks of admission to the ICU, intubation, and death, compared
106 with non-pregnant women and men.[17, 18]

107 As vaccination is one of the most effective strategies to reduce the transmission and
108 severity of infectious diseases, it is important to evaluate not only the effectiveness of
109 the vaccines in the obstetric population but also their protection against the new
110 VOCs.[19, 20] Therefore, this study compares the clinical characteristics and outcomes
111 of pregnant and postpartum women based on vaccination status and VOC, using data
112 from a Brazilian national database.

113

114 METHODS

115 Patient data were extracted from the System of Information about Epidemiological
116 Surveillance of Influenza (SIVEP-Gripe), a Brazilian national database that includes
117 surveillance data regarding severe acute respiratory syndrome (SARS).[21] Compulsory
118 reporting of SARS due to the flu (acute respiratory conditions, characterized by at least
119 two of the following signs and symptoms: fever, chills, headache, sore throat, cough,
120 coryza, anosmia, and ageusia), associated with dyspnoea, persistent chest pressure,
121 oxygen saturation (SpO₂) < 95% on room air, or cyanosis is included in this database.
122 All public and private hospitals must report all hospitalizations and deaths due to SARS-
123 CoV-2.

124 The SIVEP-Gripe includes demographic data (sex, age, skin colour/ethnicity, level of
125 education, obstetric status, and city of residence), clinical data (signs and symptoms,
126 risk factors, and comorbidities), epidemiological data (previous flu vaccinations,
127 community-acquired infection, or nosocomial infection), and laboratory and etiological
128 diagnoses. Hospital and ICU admission, requirement for ventilatory support (invasive or
129 non-invasive), and disease outcome (death or cure) are also reported. SIVEP-Gripe
130 records are publicly-available, anonymized data. Therefore, according to Brazilian
131 Ethics regulatory requirements, ethical approval by an Institutional Review Board was
132 not necessary for this study. This study followed the principles of the Declaration of
133 Helsinki.

134
135 In this study, the database was searched from 29 December 2019 to 16 July 2022
136 (epidemiological weeks 1-53 in 2020; 1-52 in 2021; and 1-28 in 2022), as the first
137 Brazilian records began in epidemiological week 8 (symptom onset for the first
138 confirmed case of COVID-19 in Brazil occurred on 17 February 2020).[22] The search
139 included all records of obstetric patients aged 10 to 49 years, who were hospitalized
140 with COVID-19 (confirmed using RT-PCR for SARS-CoV-2) (Figure 1). A total of 12,364
141 women were divided into two groups: pregnant (n=10,003) and puerperal (n=2,361).
142 Each group was subdivided based on the dominant VOCs in Brazil at the time of
143 diagnosis: original, Gamma, Delta, and Omicron. The Gamma variant was considered
144 dominant from 1 February 2021 to 31 July 2021, the Delta variant from 1 August 2021
145 to 31 December 2021, and the Omicron variant from 1 January 2022 to 16 July
146 2022.[13] Vaccination of pregnant and postpartum patients began in May 2021 in Brazil,
147 during the dominance of the Gamma variant.[18] Therefore, patients in the Gamma,
148 Delta, and Omicron subgroups were also divided based on vaccination status. Only
149 valid responses of the analysed variable were considered. The tables of analyses show
150 the number of valid observations for each variable. Variables used in the analysis were
151 age, skin colour/ethnicity, level of education, comorbidities, signs and symptoms,
152 admission to the ICU, requirement for invasive respiratory support, and outcome
153 (death). The reported comorbidities included chronic cardiovascular disease, asthma,
154 obesity, and diabetes. The reported signs and symptoms included fever, cough, sore

155 throat, dyspnoea, respiratory discomfort, SpO₂ < 95% on room air, diarrhoea, vomiting,
 156 abdominal pain, fatigue, anosmia, and ageusia.

157
 158

159 data analysis

160 Categorical variables are presented as numbers (n) and percentages (%). These were
 161 compared using the chi-square or Fisher's exact test. The odds ratio (OR) and 95%
 162 confidence interval (CI) were calculated to compare the relative odds of the occurrence
 163 of a variable of interest between the groups. All statistical analyses were conducted
 164 using R software (version 4.0.3; R Foundation for Statistical Computing Platform).[23]
 165

166 RESULTS

167 Data of 12,364 obstetric women (age range: 10-49 years), who were hospitalized with
 168 COVID-19 confirmed using RT-PCR for SARS-CoV-2, were included in this study. The
 169 pregnant group included 10,003 patients, while the puerperal group included 2,361
 170 patients. Patient age and education level were not significantly different between the
 171 groups (Table 1). The rates of the Omicron variant in different ethnic groups were
 172 significantly different between the pregnant and puerperal groups. Patients in the
 173 puerperal group had fewer comorbidities.

174
 175

Table 1. Patient characteristics

Variant	Age (years)	Pregnant	Puerperal	p
Original (n=4,741)	<20	261 (6.9%)	67 (7.2%)	0.2567 ^C
	20-34	2,526 (66.4%)	596 (63.6%)	
	≥35	1,017 (26.7%)	274 (29.2%)	
Gamma (n=5,628)	<20	243 (5.3%)	62 (6.0%)	0.5902 ^C
	20-34	2,976 (64.7%)	662 (64.6%)	
	≥35	1,384 (30.1%)	301 (29.4%)	
Delta (n=691)	<20	39 (6.8%)	11 (9.6%)	0.5666 ^C
	20-34	391 (67.9%)	75 (65.2%)	
	≥35	146 (25.3%)	29 (25.2%)	
Omicron (n=1304)	<20	85 (8.3%)	30 (10.6%)	0.3260 ^C
	20-34	722 (70.8%)	189 (66.5%)	
	≥35	213 (20.9%)	65 (22.9%)	
Variant	Skin colour/ethnicity	Pregnant	Puerperal	p
Original (n=3,842)	White	1,301 (42.1%)	289 (38.6%)	0.07546 ^F
	Black	210 (6.8%)	52 (6.9%)	
	Yellow	38 (1.2%)	3 (0.4%)	
	Brown	1,531 (49.5%)	401 (53.5%)	
	Indigenous	13 (0.4%)	4 (0.5%)	
Gamma (n=4,812)	White	1,917 (48.6%)	407 (46.8%)	0.5847 ^F
	Black	230 (5.8%)	56 (6.4%)	

	Yellow	32 (0.8%)	6 (0.7%)	
	Brown	1,754 (44.5%)	397 (45.6%)	
	Indigenous	9 (0.2%)	4 (0.5%)	
Delta (n=594)	White	242 (48.8%)	50 (51.0%)	0.9395 ^F
	Black	36 (7.3%)	5 (5.1%)	
	Yellow	3 (0.6%)	0 (0.0%)	
	Brown	211 (42.5%)	43 (43.9%)	
	Indigenous	4 (0.8%)	0 (0.0%)	
Omicron (n=1176)	White	610 (65.9%)	143 (57.0%)	0.0039 ^F
	Black	50 (5.4%)	10 (4.0%)	
	Yellow	9 (1.0%)	0 (0.0%)	
	Brown	255 (27.6%)	97 (38.6%)	
	Indigenous	1 (0.1%)	1 (0.4%)	
Variant	Education level	Pregnant	Puerperal	p
Original (n=2,002)	No schooling	7 (0.4%)	3 (0.8%)	0.5112 ^F
	Up to high school	394 (24.1%)	84 (22.7%)	
	High school	898 (55.1%)	200 (53.9%)	
	College	332 (20.4%)	84 (22.6%)	
Gamma (n=2,365)	No schooling	15 (0.8%)	6 (1.4%)	0.4348 ^F
	Up to high school	469 (24.3%)	112 (25.8%)	
	High school	1,051 (54.4%)	236 (54.4%)	
	College	396 (20.5%)	80 (18.4%)	
Delta (n=287)	No schooling	0 (0.0%)	0 (0.0%)	0.5912 ^F
	Up to high school	72 (30.1%)	11 (22.9%)	
	High school	112 (46.9%)	24 (50.0%)	
	College	55 (23.0%)	13 (27.1%)	
Omicron (n=586)	No schooling	2 (0.4%)	2 (1.9%)	0.3158 ^F
	Up to high school	135 (28.2%)	31 (28.9%)	
	High school	249 (52.0%)	51 (47.7%)	
	College	93 (19.4%)	23 (21.5%)	
Comorbidities	Variant	Pregnant	Puerperal	p
Chronic cardiovascular disease	Original (n=1,889)	239/1,306 (18.3%)	89/583 (15.3%)	0.1230 ^C
	Gamma (n=2,084)	245/1,409 (17.4%)	84/675 (12.4%)	0.0046 ^C
	Delta (n=256)	29/179 (16.2%)	8/77 (10.4%)	0.3082 ^C
	Omicron (n=441)	49/265 (18.5%)	13/176 (7.4%)	0.0017 ^C
Asthma	Original (n=1,847)	160/1,288 (12.4%)	34/559 (6.1%)	0.0001 ^C
	Gamma (n=2,040)	148/1,373 (10.8%)	37/667 (5.5%)	0.0002 ^C
	Delta (n=256)	23/181 (12.7%)	6/75 (8.0%)	0.3871 ^C
	Omicron (n=429)	26/257 (10.1%)	6/172 (3.5%)	0.0176 ^C
Diabetes	Original (n=1,887)	274/1,319 (20.8%)	65/568 (11.4%)	<0.0001 ^C
	Gamma (n=2,134)	337/1,448 (23.3%)	77/686 (11.2%)	<0.0001 ^C
	Delta (n=267)	48/188 (25.5%)	8/79 (10.1%)	0.0079 ^C
	Omicron (n=446)	62/268 (23.1%)	10/178 (5.6%)	<0.0001 ^C
Obesity	Original (n=1,822)	181/1,263 (14.3%)	64/559 (11.4%)	0.1122 ^C
	Gamma (n=2,142)	368/1,451 (25.4%)	111/691 (16.1%)	<0.0001 ^C
	Delta (n=259)	39/183 (21.3%)	8/76 (10.5%)	0.0610 ^C
	Omicron (n=425)	32/249 (12.9%)	10/176 (5.7%)	0.0229 ^C

Fever	Original (n=4,150)	2,283/3,345 (68.3%)	500/805 (62.1%)	0.76 (0.65 – 0.90)	-	-	-
	Gamma (n=2,839)	1,283/1,995 (64.3%)	241/459 (52.5%)	0.61 (0.50 – 0.76)	204/321 (63.6%)	32/64 (50.0%)	0.57 (0.32 – 1.02)
	Delta (n=529)	131/206 (63.6%)	30/47 (63.8%)	1.01 (0.50 – 2.09)	146/237 (61.6%)	20/39 (51.3%)	0.66 (0.31 – 1.38)
	Omicron (n=881)	108/190 (56.8%)	28/66 (42.4%)	0.56 (0.30 – 1.02)	244/491 (49.7%)	40/134 (29.9%)	0.43 (0.28 – 0.66)
Cough	Original (n=4,272)	2,674/3,454 (77.4%)	576/818 (70.4%)	0.69 (0.58 – 0.83)	-	-	-
	Gamma (n=2,952)	1,689/2,079 (81.2%)	335/473 (70.8%)	0.56 (0.44 – 0.71)	273/331 (82.5%)	51/69 (73.9%)	0.60 (0.32 – 1.17)
	Delta (n=568)	175/223 (78.5%)	40/52 (76.9%)	0.91 (0.43 – 2.06)	194/252 (77.0%)	28/41 (68.3%)	0.64 (0.30 – 1.45)
	Omicron (n=953)	140/205 (68.3%)	43/68 (63.2%)	0.80 (0.43 – 1.49)	359/529 (67.9%)	96/151 (63.6%)	0.83 (0.56 – 1.23)
Sore throat	Original (n=3,656)	825/2,960 (27.9%)	182/696 (26.1%)	0.92 (0.76 – 1.11)	-	-	-
	Gamma (n=2,567)	488/1,810 (27.0%)	96/414 (23.2%)	0.82 (0.63 – 1.06)	71/281 (25.3%)	13/62 (21.0%)	0.79 (0.37 – 1.58)
	Delta (n=486)	48/186 (25.8%)	8/45 (17.8%)	0.62 (0.23 – 1.48)	69/222 (31.1%)	9/33 (27.3%)	0.83 (0.32 – 1.97)
	Omicron (n=833)	70/182 (38.5%)	15/58 (25.9%)	0.56 (0.27 – 1.12)	177/462 (38.3%)	40/131 (30.5%)	0.71 (0.45 – 1.09)
Dyspnoea	Original (n=4,086)	2,024/3,305 (61.2%)	467/781 (59.8%)	0.94 (0.80 – 1.11)	-	-	-
	Gamma (n=2,913)	1,493/2,051 (72.8%)	314/470 (66.8%)	0.75 (0.60 – 0.94)	231/326 (70.9%)	44/66 (66.7%)	0.82 (0.45 – 1.52)
	Delta (n=545)	149/216 (69.0%)	36/51 (70.6%)	1.08 (0.53 – 2.27)	147/238 (61.8%)	20/40 (50.0%)	0.62 (0.29 – 1.29)
	Omicron (n=818)	58/174 (33.3%)	16/61 (26.2%)	0.71 (0.35 – 1.42)	117/443 (26.4%)	52/140 (37.1%)	1.64 (1.07 – 2.50)
Respiratory discomfort	Original (n=3,882)	1,565/3,123 (50.1%)	413/759 (54.4%)	1.19 (1.01 – 1.39)	-	-	-
	Gamma (n=2,762)	1,143/1,944 (58.8%)	267/448 (59.6%)	1.03 (0.83 – 1.28)	168/303 (55.4%)	35/67 (52.2%)	0.88 (0.50 – 1.55)
	Delta (n=510)	113/203 (55.7%)	22/47 (46.8%)	0.70 (0.35 – 1.39)	105/222 (47.3%)	11/38 (28.9%)	0.46 (0.19 – 1.00)
	Omicron (n=807)	42/170 (24.7%)	14/60 (23.3%)	0.92 (0.43 – 1.92)	127/438 (29.0%)	42/139 (30.2%)	1.06 (0.68 – 1.63)
SpO₂ <95%	Original (n=3,780)	1,020/3,043 (33.5%)	340/737 (46.1%)	1.70 (1.44 – 2.00)	-	-	-
	Gamma (n=2,780)	1,120/1,964 (57.0%)	264/451 (58.5%)	1.06 (0.86 – 1.32)	163/299 (54.5%)	34/66 (51.5%)	0.89 (0.50 – 1.57)
	Delta (n=517)	112/205 (54.6%)	32/47 (68.1%)	1.77 (0.86 – 3.74)	93/227 (41.0%)	17/38 (44.7%)	1.16 (0.55 – 2.46)
	Omicron (n=783)	31/170 (18.2%)	12/57 (21.1%)	1.19 (0.51 – 2.63)	67/426 (15.7%)	35/130 (26.9%)	1.97 (1.20 – 3.22)
Diarrhoea	Original (n=3,539)	404/2,879 (14.0%)	74/660 (11.2%)	0.77 (0.58 – 1.01)	-	-	-
	Gamma (n=2,501)	220/1,761 (12.5%)	37/406 (9.1%)	0.70 (0.47 – 1.02)	25/271 (9.2%)	7/63 (11.1%)	1.23 (0.43 – 3.11)
	Delta (n=472)	17/183 (9.3%)	5/44 (11.4%)	1.25 (0.34 – 3.82)	22/212 (10.4%)	1/33 (3.0%)	0.27 (0.01 – 1.80)
	Omicron (n=583)	13/167 (7.8%)	2/56 (3.6%)	0.44 (0.05 – 2.04)	22/416 (5.3%)	7/122 (5.7%)	1.09 (0.38 – 2.73)
Vomiting	Original (n=3,539)	399/2,884 (13.8%)	46/655 (7.0%)	0.47 (0.33 – 0.65)	-	-	-
	Gamma	249/1,771	30/407	0.49	35/271	7/61	0.87

Abdominal pain	(n=2,510)	(14.1%)	(7.4%)	(0.32 – 0.73)	(12.9%)	(11.5%)	(0.31 – 2.14)
	Delta (n=470)	21/182 (11.5%)	1/44 (2.3%)	0.18 (0.00 – 1.18)	24/211 (11.4%)	2/33 (6.1%)	0.59 (0.06 – 2.21)
	Omicron (n=770)	24/170 (14.1%)	2/55 (3.6%)	0.23 (0.03 – 0.98)	54/423 (12.8%)	6/122 (4.9%)	0.35 (0.12 – 0.85)
	Original (n=1,886)	159/1,562 (10.2%)	26/324 (8.0%)	0.77 (0.48 – 1.20)	-	-	2.17
	Gamma (n=2,476)	177/1,750 (10.1%)	35/401 (8.7%)	0.85 (0.56 – 1.25)	29/263 (11.0%)	3/62 (4.8%)	0.41 (0.08 – 1.40)
	Delta (n=466)	23/181 (12.7%)	2/44 (4.5%)	0.33 (0.04 – 1.42)	21/208 (10.1%)	4/33 (12.1%)	1.23 (0.29 – 4.02)
	Omicron (n=761)	18/168 (10.7%)	3/55 (5.5%)	0.48 (0.09 – 1.75)	56/415 (13.5%)	9/123 (7.3%)	0.51 (0.21 – 1.07)
Fatigue	Original (n=1,933)	394/1,595 (24.7%)	71/338 (21.0%)	0.81 (0.60 – 1.08)	-	-	-
	Gamma (n=2,576)	640/1,820 (35.2%)	127/411 (30.9%)	0.82 (0.65 – 1.04)	113/279 (40.5%)	21/66 (31.8%)	0.69 (0.37 – 1.25)
	Delta (n=478)	52/187 (27.8%)	17/45 (37.8%)	1.57 (0.74 – 3.27)	62/213 (29.1%)	7/33 (21.2%)	0.66 (0.23 – 1.66)
	Omicron (n=768)	38/168 (22.6%)	9/58 (15.5%)	0.63 (0.25 – 1.45)	75/417 (18.0%)	24/125 (19.2%)	1.08 (0.62 – 1.84)
Anosmia	Original (n=1,984)	442/1,636 (27.0%)	78/348 (22.4%)	0.78 (0.58 – 1.03)	-	-	-
	Gamma (n=2,517)	373/1,778 (21.0%)	55/401 (13.7%)	0.60 (0.43 – 0.82)	59/275 (21.5%)	10/63 (15.9%)	0.69 (0.30 – 1.48)
	Delta (n=468)	37/180 (20.6%)	4/44 (9.1%)	0.39 (0.09 – 1.18)	44/210 (21.0%)	6/34 (17.6%)	0.81 (0.26 – 2.16)
	Omicron (n=748)	7/164 (4.3%)	2/54 (3.7%)	0.86 (0.08 – 4.73)	14/407 (3.4%)	2/123 (1.6%)	0.46 (0.05 – 2.07)
Ageusia	Original (n=1,958)	400/1,615 (24.8%)	66/343 (19.2%)	0.72 (0.53 – 0.97)	-	-	-
	Gamma (n=2,517)	332/1,777 (18.7%)	55/403 (13.6%)	0.69 (0.50 – 0.94)	64/276 (23.2%)	8/61 (13.1%)	0.50 (0.20 – 1.13)
	Delta (n=468)	37/178 (20.8%)	5/44 (11.4%)	0.49 (0.14 – 1.37)	42/211 (19.9%)	7/35 (20.0%)	1.01 (0.35 – 2.57)
	Omicron (n=746)	7/163 (4.3%)	1/54 (1.9%)	0.42 (0.01 – 3.41)	18/406 (4.4%)	3/123 (2.4%)	0.54 (0.10 – 1.89)

Abbreviations:
OR, Odds Ratio;
95% CI, 95% confidence interval;
SpO₂, oxygen saturation in room

241 air.

242

243

244

Table 3. Outcomes of pregnant and postpartum women with COVID-19

245

Outcome	Variant	Unvaccinated			Vaccinated (with at least one dose)		
		Pregnant	Puerperal	Puerperal vs. Pregnant OR (95% CI)	Pregnant	Puerperal	Puerperal vs. Pregnant OR (95% CI)
ICU admission (n=9,202)	Original (n=4,436)	833/3,566 (23.4%)	310/870 (35.6%)	1.82 (1.54 – 2.13)	-	-	-
	Gamma (n=3,051)	795/2,157 (36.9%)	235/490 (48.0%)	1.58 (1.29 – 1.93)	91/334 (27.2%)	28/70 (40.0%)	1.78 (1.00 – 3.13)
	Delta (n=579)	90/225 (40.0%)	26/51 (51.0%)	1.56 (0.81 – 3.01)	75/256 (29.3%)	16/47 (34.0%)	1.24 (0.60 – 2.51)
	Omicron (n=1,136)	23/257 (8.9%)	18/88 (20.5%)	2.61 (1.25 – 5.38)	59/623 (9.5%)	28/168 (16.7%)	1.91 (1.13 – 3.17)
Invasive	Original (n=4,237)	300/3,389 (8.9%)	172/848 (20.3%)	2.62 (2.13 – 3.22)	-	-	-

respiratory support (n=8,904)	Gamma (n=2,964)	411/2,105 (19.5%)	163/472 (34.5%)	2.17 (1.75 – 2.70)	39/319 (12.2%)	12/68 (17.6%)	1.54 (0.76 – 3.12)
	Delta (n=576)	34/225 (15.1%)	11/51 (21.6%)	1.54 (0.72 – 3.30)	20/254 (7.9%)	4/46 (8.7%)	1.11 (0.36 – 3.42)
	Omicron (n=1127)	8/252 (3.2%)	8/87 (9.2%)	3.09 (1.12 – 8.50)	16/619 (2.6%)	12/169 (7.1%)	2.88 (1.34 – 6.21)
	Original (n=4,449)	231/3,563 (6.5%)	130/886 (14.7%)	2.48 (1.96 – 3.13)	-	-	-
Death (n=9,206)	Gamma (n=3,007)	325/2,117 (15.4%)	128/483 (26.5%)	1.99 (1.56 – 2.53)	22/341 (6.5%)	10/66 (15.2%)	2.58 (1.03 – 6.06)
	Delta (n=559)	23/222 (10.4%)	8/48 (16.7%)	1.73 (0.62 – 4.36)	7/243 (2.9%)	1/46 (2.2%)	0.75 (0.02 – 6.07)
	Omicron (n=1191)	6/267 (2.2%)	2/94 (2.1%)	0.95 (0.09 – 5.41)	7/659 (1.1%)	6/171 (3.5%)	3.38 (0.93 – 11.93)

246 Abbreviations: OR, Odds Ratio; %CI, 95% confidence interval; ICU, Intensive care unit

247

248 DISCUSSION

249 In this study, the clinical findings and outcomes of pregnant and postpartum women with
250 COVID-19 differed. These differences were influenced by the predominant VOCs at the
251 time of diagnosis (original, Gamma, Delta, and Omicron) and patient vaccination status.

252

253 **postpartum women**

254 When the COVID-19 pandemic began in 2020, it was believed that pregnant and
255 puerperal women were not at a higher risk of adverse outcomes or death than the non-
256 obstetric population.[3, 4, 24-27] However, updated studies reported higher rates of
257 invasive ventilation, ICU admissions, and death due to COVID-19 in the obstetric
258 population.[6-8, 10, 28, 29] Differences in clinical findings and outcomes between
259 pregnant and postpartum women are unclear, as previous studies regarding these
260 differences included non-hospitalized patients in whom a COVID-19 diagnosis was not
261 confirmed using RT-PCR.[8-11]

262 Another previous study compared the clinical findings and outcomes of pregnant,
263 puerperal, and non-pregnant nor puerperal women aged 10 to 49 years with COVID-19
264 from the beginning of the pandemic until 2 January 2021. This previous study used
265 propensity score matching and found that puerperal women were more likely than
266 pregnant women to be admitted to the ICU (OR: 1.97), require invasive respiratory
267 support (OR: 2.71), and die (OR: 2.51).[15]

268 The three delays model can be used to explain why postpartum women had worse
269 prognoses than pregnant women in this study.[30] During the postpartum period,
270 women may delay seeking medical assistance, as they focus on taking care of their
271 new-born, ignoring their own health care.[31, 32] The risk of thromboembolism
272 increases during the postpartum period as well as in patients with COVID-19.[33-37] As
273 the SIVEP-Gripe does not provide information regarding the date of delivery or the
274 gestational age upon diagnosis, some patients in the puerperal group may have been
275 infected with SARS-CoV-2 during pregnancy that progressed to SARS after delivery. In
276 addition, pregnant women with SARS may terminate their pregnancy as a therapeutic

277 measure and may die during the puerperal period. Caesarean sections account for
278 more than 57% of deliveries in Brazil and are even more frequent among patients with
279 severe COVID-19, which may increase the risk of maternal mortality in this
280 population.[37-40]

281 Among the unvaccinated patients in this study, those in the puerperal group had worse
282 prognosis than those in the pregnant group for each VOC. In the puerperal group,
283 35.6%, 48.0%, 51.0%, and 20.5% of unvaccinated patients with the original, Gamma,
284 Delta, and Omicron variants, respectively, were admitted to the ICU; 20.3%, 34.5%,
285 21.6%, and 9.2%, respectively, required invasive ventilation; and 14.7%, 26.5%, 16.7%,
286 and 2.1%, respectively, died. The mortality rate was significantly lower in unvaccinated
287 pregnant patients, with the exception of patients with the Omicron variant.

288 Studies including the general population have reported that different VOCs and
289 vaccination statuses affect the clinical symptoms and outcomes of patients with COVID-
290 19.[41-42] A review concluded that the Alpha, Beta, and Gamma variants were
291 associated with higher risks of hospitalization and ICU admission, compared with the
292 original variant and that the Beta variant had the highest risk of ICU admission.[43] A
293 meta-analysis reported higher risks of hospitalization, ICU admission, and mortality for
294 patients infected with the Beta and Delta variants, compared with those infected with the
295 Alpha and Gamma variants. The meta-analysis also concluded that all SARS-CoV-2
296 VOCs are associated with a higher risk of severe outcomes, compared with the original
297 SARS-CoV-2 variant.[44]

298 In this study, postpartum patients were less likely to have comorbidities, although the
299 comorbidities varied between the VOC subgroups. Patients in the puerperal group also
300 presented with different clinical findings based on the VOC and their vaccination status.
301 Patients in the puerperal group who were unvaccinated were more likely to have an
302 $SpO_2 < 95\%$ on room air. This was true in all VOC subgroups. Unvaccinated patients in
303 the puerperal group with the original, Gamma, and Omicron were more likely to be
304 admitted to the ICU and to require invasive ventilatory support, and those with the
305 original and Gamma variants were more likely to die.

306 Among the vaccinated puerperal patients, those in Omicron variant subgroup had a
307 higher risk of having an $SpO_2 < 95\%$ on room air. Vaccinated puerperal patients in the
308 Omicron subgroup also had a higher risk of ICU admission and requiring invasive
309 ventilatory support. Those in the Gamma subgroup had an increased risk of death.
310 These findings suggest that puerperal women have a higher risk of severe outcomes
311 than pregnant women, especially when unvaccinated.

312 Previous observational studies and surveillance data regarding vaccination during
313 pregnancy are reassuring. Most patients in the previous studies were administered the
314 Pfizer/BioNTech or Moderna vaccines, and no adverse outcomes or side effects of
315 vaccination during pregnancy were reported.[45-48] In Brazil, pregnant women are
316 administered the Sinovac/Butantan and Pfizer/Wyeth vaccines.[49] In hospitalized

317 pregnant and postpartum patients with severe COVID-19, those who received two
318 doses of a COVID-19 vaccine had a 46% reduction in the odds of ICU admission, an
319 81% reduction in the odds of requiring invasive ventilatory support, and an 80%
320 reduction in the odds of death, compared with those who did not receive any COVID-19
321 vaccination.[19] Among the general population, several studies have indicated that
322 COVID-19 vaccination protects against severe outcomes caused by SARS-CoV-2
323 variants, including the Omicron variant.[50-52] The results of the current study support
324 these previous findings and suggest that vaccines effectively reduce adverse outcomes
325 including ICU admission, the requirement for invasive ventilatory support, and death in
326 pregnant and puerperal patients. Therefore, vaccination is an important public health
327 strategy globally, and pregnant and postpartum women should be included in
328 randomized clinical trials.[19, 53].

329 This study has several strengths, including the use of a large dataset with nationwide
330 coverage and no duplicates that included hospitalized obstetric patients with COVID-19
331 confirmed via RT-PCR, VOC data, and vaccination status. Similar studies neither
332 reported these data nor divided the obstetric population into pregnant and puerperal
333 groups.

334 However, this study has limitations, including its retrospective nature based on a
335 secondary database analysis. Although reporting COVID-19-related hospital admissions
336 is compulsory in Brazil, it is not guaranteed that all patients with COVID-19 who were
337 hospitalized were included in the database. Bias due to missing or inaccurate data
338 cannot be ruled out. Asymptomatic or mildly symptomatic patients are not reported in
339 the SIVEP-Gripe; therefore, an analysis of the non-hospitalized population was not
340 possible. In addition, the database used in this study does not include information
341 regarding other obstetric variables such as gestational age, delivery mode, date of birth,
342 comorbidities, week of pregnancy at diagnosis, and perinatal data. As it is an
343 anonymous database, the data cannot be linked with the public database of birth
344 registers and mode of delivery.

345 As postpartum women have higher risks of developing severe forms of COVID-19,
346 especially when unvaccinated, health care strategies to implement vaccination and
347 manage postpartum patients with COVID-19 are necessary. The risk of severe COVID-
348 19 in puerperal patients should not be underestimated, and health care workers should
349 closely monitor all postpartum women infected with SARS-CoV-2, especially those who
350 are not vaccinated. The vaccination of pregnant and postpartum patients should
351 become a public health priority.

352

353 **Acknowledgements**

354 None

355 **Competing interests**

356 The authors have declared that no competing interests exist.

357 **Funding**

358 This work was supported, in whole or in part, by the Bill & Melinda Gates Foundation
359 [INV-027961]. Under the grant conditions of the Foundation, a Creative Commons
360 Attribution 4.0 Generic License has already been assigned to the Author Accepted
361 Manuscript version that might arise from this submission. This work is also funded by
362 CNPq (Award Number: 445881/2020-8) and FAPES (Award Number:
363 44437.699.40413.22122020). The funders had no role in study design, data collection
364 and analysis, decision to publish, or preparation of the manuscript.

365 **Data availability**

366 The data that support the findings of this study are available in GitHub repository at
367 [https://github.com/observatorioobstetrico/COVID-19-impact-of-original-Gamma-Delta-](https://github.com/observatorioobstetrico/COVID-19-impact-of-original-Gamma-Delta-and-Omicron-variants-of-SARS-CoV-2-in-vaccinated-and-unv)
368 [and-Omicron-variants-of-SARS-CoV-2-in-vaccinated-and-unv](https://github.com/observatorioobstetrico/COVID-19-impact-of-original-Gamma-Delta-and-Omicron-variants-of-SARS-CoV-2-in-vaccinated-and-unv). These data were derived
369 from the following resources available in the public domain:
370 <https://opendatasus.saude.gov.br/dataset/srag-2020> and
371 <https://opendatasus.saude.gov.br/dataset/srag-2021-e-2022> obtained on 25 July 2022.

372

373 **REFERENCES**

374

375 1 World Health Organization. WHO Director-General's opening remarks at the media briefing
376 on COVID-19 - 11 March 2020. Accessed: 23 March 2022. Available from:
377 [https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)
378 [remarks-at-the-media-briefing-on-covid-19---11-march-2020](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)

379 2 World Health Organization. WHO COVID-19 Dashboard. Accessed: 26 August 2022. Available
380 from: <https://covid19.who.int/>

381 3 Zaigham M, Andersson O. Maternal and perinatal outcomes with COVID-19: A systematic
382 review of 108 pregnancies. *Acta Obstet Gynecol Scand* 2020;99:823–9.

383 4 Kasraeian M, Zare M, Vafaei H, et al. COVID-19 pneumonia and pregnancy; a systematic
384 review and meta-analysis. *J Matern Fetal Neonatal Med* 2022;35:1652–9.

385 5 Mullins E, Evans D, Viner RM, et al. Coronavirus in pregnancy and delivery: rapid review.
386 *Ultrasound Obstet Gynecol* 2020;55:586–92.

387 6 Badr DA, Mattern J, Carlin A, et al. Are clinical outcomes worse for pregnant women at ≥ 20
388 weeks' gestation infected with coronavirus disease 2019? A multicenter case-control study with
389 propensity score matching. *Am J Obstet Gynecol* 2020;223:764–68.

390 7 Sentilhes L, De Marcillac F, Jouffrieau C, et al. Coronavirus disease 2019 in pregnancy was
391 associated with maternal morbidity and preterm birth. *Am J Obstet Gynecol* 2020;223:914.e1–
392 15.

- 393 8 Zambrano LD, Ellington S, Strid P, et al. Update: Characteristics of Symptomatic Women of
394 Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status -
395 United States, January 22-October 3, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:1641–7.
- 396 9 Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and
397 perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and
398 meta-analysis. *BMJ* 2020;370:m3320.
- 399 10 Martinez-Portilla RJ, Sotiriadis A, Chatzakis C, et al. Pregnant women with SARS-CoV-2
400 infection are at higher risk of death and pneumonia: propensity score matched analysis of a
401 nationwide prospective cohort (COV19Mx). *Ultrasound Obstet Gynecol* 2021;57:224–31.
- 402 11 Rozo N, Valencia D, Newton SM, et al. Severity of illness by pregnancy status among
403 laboratory-confirmed SARS-CoV-2 infections occurring in reproductive-aged women in
404 Colombia *Paediatr Perinat Epidemiol* 2022;36:456–65. 2021
- 405 12 World Health Organization. Tracking SARS-CoV-2 variants. Accessed: 21 May 2022. Available
406 from: <http://who.int/en/activities/tracking-SARS-CoV-2-variants/>
- 407 13 FIOCRUZ. FIOCRUZ: Genomic Network. Accessed: 22 May 2022. Available from:
408 <http://www.genomahcov.fiocruz.br/>
- 409 14 Takemoto M, Menezes MO, Andreucci CB, et al. Clinical characteristics and risk factors for
410 mortality in obstetric patients with severe COVID-19 in Brazil: a surveillance database analysis.
411 *BJOG* 2020;127:1618–26.
- 412 15 Serra FE, Francisco RPV, de Rossi P, et al. COVID-19 outcomes in hospitalized puerperal,
413 pregnant, and neither pregnant nor puerperal women. *PLoS One* 2021;16:e0259911.
- 414 16 Francisco R, Lacerda L, Rodrigues AS. Obstetric Observatory BRAZIL - COVID-19: 1031
415 maternal deaths because of COVID-19 and the unequal access to health care services. *Clinics*
416 *(Sao Paulo)* 2021;76:e3120.
- 417 17 Gonçalves BMM, Franco RPV, Rodrigues AS. Maternal mortality associated with COVID-19 in
418 Brazil in 2020 and 2021: Comparison with non-pregnant women and men. *PLoS One*
419 2021;16:e0261492.
- 420 18 Brazil. Ministry of Health. Department of Health Surveillance. Department of Immunization
421 and Transmitted Diseases. General Coordination of the National immunization Program: NOTA
422 TÉCNICA Nº 467/2021-CGPNI/DEIDT/SVS/MS. Accessed: 22 May 2022. Available from:
423 [https://www.gov.br/saude/pt-br/media/pdf/2021/abril/27/nota-tecnica-467-2021-cgpni-deidt-](https://www.gov.br/saude/pt-br/media/pdf/2021/abril/27/nota-tecnica-467-2021-cgpni-deidt-svs-ms.pdf)
424 [svs-ms.pdf](https://www.gov.br/saude/pt-br/media/pdf/2021/abril/27/nota-tecnica-467-2021-cgpni-deidt-svs-ms.pdf)
- 425 19 Kalafat E, Heath P, Prasad S, et al. COVID-19 vaccination in pregnancy. *Am J Obstet Gynecol*
426 2022;227:136–47.

- 427 20 de Freitas Paganoti C, Alkmin da Costa R, Papageorghiou AT, et al. COVID-19 Vaccines Confer
428 Protection in Hospitalized Pregnant and Postpartum Women with Severe COVID-19: A
429 Retrospective Cohort Study. *Vaccines (Basel)* 2022;10:749.
- 430 21 Brazil. Ministry of Health. Definition of Case and Notification. Accessed: 4 April 2021.
431 Available from: [https://www.gov.br/saude/pt-br/coronavirus/artigos/definicao-e-casos-](https://www.gov.br/saude/pt-br/coronavirus/artigos/definicao-e-casos-suspeitos)
432 [suspeitos](https://www.gov.br/saude/pt-br/coronavirus/artigos/definicao-e-casos-suspeitos)
- 433 22 Brazil. Ministry of Health. SINAN – Notifiable Diseases Information System. Epidemiological
434 Calendar 2022. Accessed: 30 August 2022. Available from:
435 <http://www.portalsinan.saude.gov.br/calendario-epidemiologico>
- 436 23 R Core Team. R: A language and environment for statistical computing. R Foundation for
437 Statistical Computing, Vienna, Austria, 2020. Version 4.1.3. Accessed on: 30 July 2022. Available
438 from: <https://www.r-project.org/>.
- 439 24 Chen H, Guo J, Wang C, et al. Clinical characteristics, and intrauterine vertical transmission
440 potential of COVID-19 infection in nine pregnant women: a retrospective review of medical
441 records. *Lancet* 2020;395:809–15.
- 442 25 Di Toro F, Gjoka M, Di Lorenzo G, et al. Impact of COVID-19 on maternal and neonatal
443 outcomes: a systematic review and meta-analysis. *Clin Microbiol Infect* 2021;27:36–46.
- 444 26 Elshafeey F, Magdi R, Hindi N, et al. A systematic scoping review of COVID-19 during
445 pregnancy and childbirth. *Int J Gynaecol Obstet* 2020;150:47–52.
- 446 27 Huntley BJF, Huntley ES, Di Mascio D, et al. Rates of Maternal and Perinatal Mortality and
447 Vertical Transmission in Pregnancies Complicated by Severe Acute Respiratory Syndrome
448 Coronavirus 2 (SARS-Co-V-2) Infection: A Systematic Review. *Obstet Gynecol* 2020;136:303–12.
- 449 28 Hantoushzadeh S, Shamshirsaz AA, Aleyasin A, et al. Maternal death due to COVID-19. *Am J*
450 *Obstet Gynecol* 2020;223:109.e1–16.
- 451 29 Collin J, Byström E, Carnahan A, et al. Public Health Agency of Sweden's Brief Report:
452 Pregnant and postpartum women with severe acute respiratory syndrome coronavirus 2
453 infection in intensive care in Sweden. *Acta Obstet Gynecol Scand* 2020;99:819–22.
- 454 30 Thaddeus S, Maine D. Too far to walk: maternal mortality in context. *Soc Sci Med*
455 1994;38:1091–110.
- 456 31 Finlayson K, Crossland N, Bonet M, et al. What matters to women in the postnatal period: A
457 meta-synthesis of qualitative studies. *PLoS One* 2020;15:e0231415.
- 458 32 Pacagnella RC, Cecatti JG, Parpinelli MA, et al. Delays in receiving obstetric care and poor
459 maternal outcomes: results from a national multicentre cross-sectional study. *BMC Pregnancy*
460 *Childbirth* 2014;14:159.

- 461 33 Kamel H, Navi BB, Sriram N, et al. Risk of a thrombotic event after the 6-week postpartum
462 period. *N Engl J Med* 2014;370:1307–15.
- 463 34 Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-
464 CoV-2 infection: a multicenter prospective cohort study. *Intensive Care Med* 2020;46:1089–98.
- 465 35 Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor
466 prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost* 2020;18:844–7.
- 467 36 Katz D, Beilin Y. Disorders of coagulation in pregnancy. *Br J Anaesth* 2015;115:75–88.
- 468 37 Sobhy S, Arroyo-Manzano D, Murugesu N, et al. Maternal and perinatal mortality and
469 complications associated with caesarean section in low-income and middle-income countries: a
470 systematic review and meta-analysis. *Lancet* 2019;393:1973–82.
- 471 38 Nahshon C, Bitterman A, Haddad R, et al. Hazardous Postoperative Outcomes of Unexpected
472 COVID-19 Infected Patients: A Call for Global Consideration of Sampling all Asymptomatic
473 Patients Before Surgical Treatment. *World J Surg* 2020;44:2477–81.
- 474 39 Aminian A, Safari S, Razeghian-Jahromi A, et al. COVID-19 Outbreak and Surgical Practice:
475 Unexpected Fatality in Perioperative Period. *Ann Surg* 2020;272:e27–9.
- 476 40 Brazil. Ministry of Health, 2020. DATASUS. Live Birth Information System – SINASC. Accessed:
477 23 July 2022. Available from: <http://tabnet.datasus.gov.br/cgi/tabcgi.exe?sinasc/cnv/nvuf.def>
- 478 41 Loconsole D, Centrone F, Morcavallo C, et al. Changing Features of COVID-19:
479 Characteristics of Infections with the SARS-CoV-2 Delta (B.1.617.2) and Alpha (B.1.1.7) Variants
480 in Southern Italy. *Vaccines* 2021;9:1354.
- 481 42 Wang S, Zou X, Li Z, et al. Analysis of Clinical Characteristics and Virus Strains Variation of
482 Patients Infected With SARS-CoV-2 in Jiangsu Province-A Retrospective Study. *Front Public*
483 *Health* 2021;9:791600.
- 484 43 Cantón R, De Lucas Ramos P, García-Botella A, et al. New variants of SARS-CoV-2. *Rev Esp*
485 *Quimioter* 2021;34:419–28.
- 486 44 Lin L, Liu Y, Tang X, et al. The Disease Severity and Clinical Outcomes of the SARS-CoV-2
487 Variants of Concern. *Front Public Health* 2021;9:775224.
- 488 45 Gray KJ, Bordt EA, Atyeo C, et al. Coronavirus disease 2019 vaccine response in pregnant and
489 lactating women: a cohort study. *Am J Obstet Gynecol* 2021;225:303.e1–17.
- 490 46 Mackin DW, Walker SP. The historical aspects of vaccination in pregnancy. *Best Pract Res*
491 *Clin Obstet Gynaecol* 2021;76:13–22.

- 492 47 Blakeway H, Prasad S, Kalafat E, et al. COVID-19 vaccination during pregnancy: coverage and
493 safety. *Am J Obstet Gynecol* 2022;226:236.e1–14.
- 494 48 Lipkind HS, Vazquez-Benitez G, DeSilva M, et al. Receipt of COVID-19 Vaccine During
495 Pregnancy and Preterm or Small-for-Gestational-Age at Birth - Eight Integrated Health Care
496 Organizations, United States, December 15, 2020-July 22, 2021. *MMWR Morb Mortal Wkly Rep*
497 2022;71:26–30.
- 498 49 Brazil. Ministry of Health. Department of Health Surveillance. Department of Immunization
499 and Transmitted Diseases. General Coordination of the National immunization Program: *Nota*
500 *Técnica* Nº 651/2021-CGPNI/DEIDT/SVS/MS. Accessed: 30 July 2022. Available from:
501 [https://www.gov.br/saude/pt-br/media/pdf/2021/maio/19/nota-tecnica-651-2021-cgpni-](https://www.gov.br/saude/pt-br/media/pdf/2021/maio/19/nota-tecnica-651-2021-cgpni-deidt-svs-ms.pdf)
502 [deidt-svs-ms.pdf](https://www.gov.br/saude/pt-br/media/pdf/2021/maio/19/nota-tecnica-651-2021-cgpni-deidt-svs-ms.pdf)
- 503 50 León TM, Dorabawila V, Nelson L, et al. COVID-19 cases and hospitalizations by COVID-19
504 vaccination status and previous COVID-19 diagnosis—California and New York, May–November
505 2021. *MMWR Morb Mortal Wkly Rep* 2022;71:125–31.
- 506 51 Thompson MG, Natarajan K, Irving SA, et al. Effectiveness of a third dose of mRNA vaccines
507 against COVID-19—associated emergency department and urgent care encounters and
508 hospitalizations among adults during periods of Delta and Omicron variant predominance—
509 VISION Network, 10 states, August 2021–January 2022. *MMWR Morb Mortal Wkly Rep*
510 2022;71:139–45.
- 511 52 Danza P, Koo TH, Haddix M, et al. SARS-CoV-2 Infection and Hospitalization Among Adults
512 Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron)
513 Variant Predominance - Los Angeles County, California, November 7, 2021-January 8,
514 2022. *MMWR Morb Mortal Wkly Rep* 2022;71:177–81.
- 515 53 Beigi RH, Krubiner C, Jamieson DJ, et al. The need for inclusion of pregnant women in COVID-
516 19 vaccine trials. *Vaccine* 2021;39:868–70.
- 517
- 518
- 519

520 **Figure legend**

521 **Figure 1. Study Profile: case selection flowchart**

522 **Abbreviations:** SIVEP-Gripe: System of Information about Epidemiological
523 Surveillance of Influenza; SARS: severe acute respiratory syndrome; COVID-19:
524 Coronavirus disease 2019; RT-PCR: polymerase chain reaction

